| 產品編號 | bs-0723R-Cy5 |
| 英文名稱 | Rabbit Anti-P63/Cy5 Conjugated antibody |
| 中文名稱 | Cy5標記的腫瘤抑制基因p63α抗體 |
| 別 名 | P63 protein; AIS; Amplified in squamous cell carcinoma; B(p51A); B(p51B); p63 Alpha; Chronic ulcerative stomatitis protein; CUSP; DN p63 alpha 1; DNp63; EEC3; Keratinocyte transcription factor; Keratinocyte transcription factor KET; KET; LMS; NBP; OFC8; p40; p51; P51/P63; p53 like transcription factor; p53 related protein; p53-related protein p63; p53CP; p63; P73; p73H; p73L; RHS; SHFM4; TP53CP; TP53L; TP63; TP73; TP73L; Transformation related protein 63; Trp53rp1; Trp63; Tumor protein 63; tumor protein 63 kDa with strong homology to p53; Tumor protein p53-competing protein; Tumor protein p53-like; tumor protein p63; Tumor protein p73; tumor protein p73-like; P63_HUMAN. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領域 | 腫瘤 細胞生物 免疫學 信號轉導 轉錄調節(jié)因子 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human, Rat, (predicted: Mouse, Dog, Pig, Cow, Horse, Rabbit, Sheep, Guinea Pig, ) |
| 產品應用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 77kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human P63 protein |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產品介紹 |
background: This gene encodes a member of the p53 family of transcription factors. An animal model, p63 -/- mice, has been useful in defining the role this protein plays in the development and maintenance of stratified epithelial tissues. p63 -/- mice have several developmental defects which include the lack of limbs and other tissues, such as teeth and mammary glands, which develop as a result of interactions between mesenchyme and epithelium. Mutations in this gene are associated with ectodermal dysplasia, and cleft lip/palate syndrome 3 (EEC3); split-hand/foot malformation 4 (SHFM4); ankyloblepharon-ectodermal defects-cleft lip/palate; ADULT syndrome (acro-dermato-ungual-lacrimal-tooth); limb-mammary syndrome; Rap-Hodgkin syndrome (RHS); and orofacial cleft 8. Both alternative splicing and the use of alternative promoters results in multiple transcript variants encoding different proteins. Many transcripts encoding different proteins have been reported but the biological validity and the full-length nature of these variants have not been determined. [provided by RefSeq, Jul 2008]. Function: Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge. Subunit: Binds DNA as a homotetramer. Isoform composition of the tetramer may determine transactivation activity. Isoforms Alpha and Gamma interact with HIPK2. Interacts with SSRP1, leading to stimulate coactivator activity. Isoform 1 and isoform 2 interact with WWP1. Interacts with PDS5A. Isoform 5 (via activation domain) interacts with NOC2L. Subcellular Location: Nucleus. Tissue Specificity: Widely expressed, notably in heart, kidney, placenta, prostate, skeletal muscle, testis and thymus, although the precise isoform varies according to tissue type. Progenitor cell layers of skin, breast, eye and prostate express high levels of DeltaN-type isoforms. Isoform 10 is predominantly expressed in skin squamous cell carcinomas, but not in normal skin tissues. Post-translational modifications: May be sumoylated. Ubiquitinated. Polyubiquitination involves WWP1 and leads to proteasomal degradation of this protein. DISEASE: Defects in TP63 are the cause of acro-dermato-ungual-lacrimal-tooth syndrome (ADULT syndrome) [MIM:103285]; a form of ectodermal dysplasia. Ectodermal dysplasias (EDs) constitute a heterogeneous group of developmental disorders affecting tissues of ectodermal origin. EDs are characterized by abnormal development of two or more ectodermal structures such as hair, teeth, nails and sweat glands, with or without any additional clinical sign. Each combination of clinical features represents a different type of ectodermal dysplasia. ADULT syndrome involves ectrodactyly, syndactyly, finger- and toenail dysplasia, hypoplastic breasts and nipples, intensive freckling, lacrimal duct atresia, frontal alopecia, primary hypodontia, and loss of permanent teeth. ADULT differs significantly from EEC3 syndrome by the absence of facial clefting. Similarity: Belongs to the p53 family. Contains 1 SAM (sterile alpha motif) domain. Database links: Entrez Gene: 8626 Human Entrez Gene: 22061 Mouse Omim: 603273 Human SwissProt: Q9H3D4 Human SwissProt: O88898 Mouse Unigene: 137569 Human Unigene: 20894 Mouse Unigene: 42907 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. P63—也是腫瘤抑制因子之一.p63基因是抑癌基因p53的同源性基因，主要表達上皮組織的基底細胞或復層上皮細胞，如皮膚、食道、宮頸外口、扁桃體、膀胱等，和前列腺、乳腺腺樣結構的基層細胞。 |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
